FDA
-
-
-
-
-
-
-
Chardan Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT) amid FDA accelerated approval
-
-
-
-
-
-
-
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
Goldman Sachs Reiterates Sell Rating on Rocket Pharmaceuticals (RCKT), PT $2,
-
-
-
-
-
-
-
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
-
-
-
-
-
-
-
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
-
-
-
-
-
-
CLASS ACTION NOTICE: Berger Montague Advises Rocket Pharmaceuticals (RCKT) Investors to Inquire About a Securities Fraud Class Action
-
-
-
-
-
-
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

